Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06767527 | AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer | recruiting | Phase 3 | 416 | AkesoINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07459296 | Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC | recruiting | Phase 3 | 266 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07472140 | PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer | recruiting | Phase 2 / Phase 3 | 120 | N.N. Alexandrov National Cancer CentreOTHER_GOV | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06030440 | De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck(DIREKHT2) | recruiting | Phase 2 / Phase 3 | 508 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07319429 | Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification(FEMUS) | recruiting | Phase 2 / Phase 3 | 260 | Fudan UniversityOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07463235 | Safety and Potency of a High Cabergoline Dosage in Microprolactinomas(SPARAGMOS) | recruiting | Phase 3 | 70 | University of Sao Paulo General HospitalOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07467330 | Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment | recruiting | Phase 3 | 258 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07461948 | Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients | recruiting | Phase 3 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05871099 | Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not | recruiting | Phase 3 | 616 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06239727 | Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response | recruiting | Phase 3 | 593 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07010263 | A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy(AK112-311) | recruiting | Phase 3 | 560 | AkesoINDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06951503 | AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer | recruiting | Phase 3 | 560 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06953999 | A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer | recruiting | Phase 3 | 999 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07327216 | Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 180 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04215731 | Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer(FOBEAR) | recruiting | Phase 3 | 582 | Yanhong DengOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07174908 | A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation | recruiting | Phase 3 | 400 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03495427 | PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores | recruiting | Phase 2 / Phase 3 | 60 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07132684 | Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients | recruiting | Phase 3 | 240 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | recruiting | Phase 3 | 550 | Shanghai Henlius BiotechINDUSTRY | 17 | Feb 27, 2026 | clinicaltrials |
| NCT06554652 | Selective Neck Dissection Versus Modified Neck Dissection in PTC | recruiting | Phase 3 | 250 | Fudan UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06558981 | Adjuvant Radiotherapy in High Risk Locally Advanced DTC | recruiting | Phase 3 | 124 | Fudan UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07441291 | CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT | recruiting | Phase 3 | 70 | Peking University People's HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03016819 | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)(APROMISS) | recruiting | Phase 3 | 325 | Advenchen Laboratories, LLCINDUSTRY | 5 | Feb 25, 2026 | clinicaltrials |
| NCT05549297 | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | recruiting | Phase 3 | 540 | Immunocore LtdINDUSTRY | 12 | Feb 25, 2026 | clinicaltrials |
| NCT06112314 | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)(PRISM-MEL-301) | recruiting | Phase 3 | 680 | Immunocore LtdINDUSTRY | 26 | Feb 25, 2026 | clinicaltrials |
| NCT07377643 | IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer | recruiting | Phase 3 | 540 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06650579 | REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial | recruiting | Phase 3 | 72 | Emory UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07414758 | Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy(T-START-M1) | recruiting | Phase 3 | 68 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05991388 | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma(Glo-BNHL) | recruiting | Phase 2 / Phase 3 | 210 | University of BirminghamOTHER | 7 | Feb 20, 2026 | clinicaltrials |
| NCT06513065 | Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)(HIPEC-PMP) | recruiting | Phase 3 | 176 | University of SouthamptonOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07417397 | Adjuvant TACE in HCC With High-risk Recurrence Factors | recruiting | Phase 3 | 442 | Guangxi Medical UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07029217 | A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas | recruiting | Phase 3 | 375 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07413809 | Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen | recruiting | Phase 3 | 92 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05827523 | Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)(FOCUS / KOV-04) | recruiting | Phase 3 | 520 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06593665 | Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.(RPLND) | recruiting | Phase 3 | 142 | Indiana UniversityOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06135714 | Metastasis-directed Therapy for Oligometastases of Breast Cancer(OLIGAMI) | recruiting | Phase 3 | 340 | Tokyo Medical and Dental UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06937905 | Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)(TARLANEC) | recruiting | Phase 3 | 129 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07402876 | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma | recruiting | Phase 3 | 20 | Aldeyra Therapeutics, Inc.INDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06107920 | Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy(COnCERTO) | recruiting | Phase 3 | 232 | University Hospital, RouenOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | recruiting | Phase 3 | 550 | Jazz PharmaceuticalsINDUSTRY | 15 | Feb 10, 2026 | clinicaltrials |
| NCT06860269 | A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia(GRAALL-2024) | recruiting | Phase 2 / Phase 3 | 1,200 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04706910 | 18F-DOPA II - PET Imaging Optimization | recruiting | Phase 3 | 800 | University of AlbertaOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07377578 | A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma | recruiting | Phase 3 | 394 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06349668 | Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery(SMILe) | recruiting | Phase 3 | 220 | Hans BahlmannOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07005024 | DOAC - Dosing Options in AntiCoagulation Prophylaxis(DOAC) | recruiting | Phase 3 | 996 | University of VermontOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07389265 | Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer(CAPRI-3 GOIM) | recruiting | Phase 3 | 480 | University of Campania Luigi VanvitelliOTHER | 2 | Feb 5, 2026 | clinicaltrials |
| NCT07389616 | A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma | recruiting | Phase 2 / Phase 3 | 40 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06563388 | Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial(ID-COMET) | recruiting | Phase 3 | 800 | Roswell Park Cancer InstituteOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05331521 | A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).(ImproveCodel) | recruiting | Phase 3 | 406 | University Hospital HeidelbergOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06904170 | Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma(ALICE) | recruiting | Phase 2 / Phase 3 | 196 | UNICANCEROTHER | 1 | Feb 3, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Mar 16, 2026source: clinicaltrials